Closing the gap in eyecare

Developing novel, orally administered ophthalmology drugs to meet the needs of millions of patients at risk of vision loss.

Addressing the large unmet medical need to develop more effective and less burdensome therapies for patients and their caregivers.

Developing danegaptide, an orally administered, small molecule drug with a novel mode of action.

Developing orally administered P₂X₇ receptor antagonists with anti-inflammatory and neuroprotective properties.